SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: jaybe who wrote (4307)6/9/2016 6:11:31 PM
From: Biomaven  Read Replies (1) | Respond to of 4474
 
If you compare only the patients with a single prior TKI, the drugs look pretty comparable on efficacy.

But side effects here pretty ugly, especially as they don't seem to reflect multiple patient complaints of cognitive impact. ("Slow speech" is only mention).



To: jaybe who wrote (4307)6/10/2016 12:55:52 PM
From: jesspro  Read Replies (1) | Respond to of 4474
 
Jaybe, is Alectinib fairly even with Brigatinib in all categories other than CNS penetration? TIA.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News